APA (7th ed.) Citation

TS, C., TH, L., JS, L., PL, K., & YL, K. (2017). Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: High efficacy with minimal toxicity. Annals of hematology, 96(4), 647. https://doi.org/10.1007/s00277-017-2931-z

Chicago Style (17th ed.) Citation

TS, Chan, Luk TH, Lau JS, Khong PL, and Kwong YL. "Low-dose Pembrolizumab for Relapsed/refractory Hodgkin Lymphoma: High Efficacy with Minimal Toxicity." Annals of Hematology 96, no. 4 (2017): 647. https://doi.org/10.1007/s00277-017-2931-z.

MLA (9th ed.) Citation

TS, Chan, et al. "Low-dose Pembrolizumab for Relapsed/refractory Hodgkin Lymphoma: High Efficacy with Minimal Toxicity." Annals of Hematology, vol. 96, no. 4, 2017, p. 647, https://doi.org/10.1007/s00277-017-2931-z.